These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 15221957)
1. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. Ohashi A; Kinoshita K; Isozaki K; Nishida T; Shinomura Y; Kitamura Y; Hirota S Int J Cancer; 2004 Sep; 111(3):317-21. PubMed ID: 15221957 [TBL] [Abstract][Full Text] [Related]
2. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043 [TBL] [Abstract][Full Text] [Related]
7. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423 [TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Matei D; Chang DD; Jeng MH Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091 [TBL] [Abstract][Full Text] [Related]
9. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968 [TBL] [Abstract][Full Text] [Related]
10. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Heinrich MC; Griffith D; McKinley A; Patterson J; Presnell A; Ramachandran A; Debiec-Rychter M Clin Cancer Res; 2012 Aug; 18(16):4375-84. PubMed ID: 22745105 [TBL] [Abstract][Full Text] [Related]
11. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]
12. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936 [TBL] [Abstract][Full Text] [Related]